Characterising the safety of clomiphene citrate in male patients through prostate-specific antigen, haematocrit, and testosterone levels

This study evaluated clomiphene citrate (CC) for safety in male patients with infertility or hypogonadism. Over 12 months, it found that CC significantly increased testosterone without affecting PSA or haematocrit levels. The study included 77 men aged 22-51, all treated with 50 mg daily or every other day. CC showed